Literature DB >> 3552444

Cryoprecipitate infusion fails to improve organ function in septic shock.

F Hesselvik, B Brodin, C Carlsson, B Cedergren, L Jorfeldt, G Liedén.   

Abstract

Plasma fibronectin may be of critical importance for the septic patient through its proposed function as the major opsonin for macrophage clearance of circulating, noncellular debris. As a rule, critically ill, septic patients are depleted of fibronectin. In earlier uncontrolled studies, infusion of fibronectin-rich cryoprecipitate had resulted in improved renal and pulmonary functions and changes in peripheral hemodynamics. In this controlled study, 32 septic ICU patients (mean initial fibronectin level = 60% of normal) received cryoprecipitate or control infusions. Although the fibronectin level was significantly elevated to the normal range in the cryoprecipitate group, no effects were seen in hemodynamics, oxygen metabolism, or lung and kidney functions. Our results indicate that this form of fibronectin therapy does not influence the impaired organ function in septic shock.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552444     DOI: 10.1097/00003246-198705000-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Plasma fibronectin concentrations in blood products.

Authors:  J Perttilä; M Salo; O Peltola
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Report on the European Conference on Septic Shock of the European Society of Intensive Care Medicine and the European Shock Society, Brussels, Belgium, March 1-2, 1987.

Authors:  I M Ledingham; K Messmer; L Thijs
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

3.  The influence of fibronectin administration on the incidence of sepsis and septic mortality in severely injured patients. The Medical College of Georgia Fibronectin Research Group.

Authors:  A R Mansberger; J E Doran; R Treat; M Hawkins; J R May; B D Callaway; M Horowitz; B Horowitz; R Shulman
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.